With respect to DOCK-4, its upregulation was found to correlate with first recurrence in bone in patients not receiving the BP (HR 2.13, 95% CI 1.06–4.30, p = 0.034), but this association was absent in zoledronate arm (HR 0.812, 95%CI 0.176–3.76, p = 0.790), confirming the efficacy of the drug in preventing BM in high-risk patients; it is of note that DOCK-4 overexpression did not correlate with extraskeletal dissemination of BC (p = 0.08) [87]. Here, DOCK4 is linked to breast cancer.